Anticardiolipin antibodies in the sera of patients with diagnosed chronic fatigue syndrome
β Scribed by Yoshitsugi Hokama; Cara Empey Campora; Cynthia Hara; Tina Kuribayashi; Diana Le Huynh; Kenichi Yabusaki
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 78 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0887-8013
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Examination of anticardiolipin antibodies (ACAs) in the sera of patients clinically diagnosed with chronic fatigue syndrome (CFS) using an enzymeβlinked immunoassay procedure demonstrated the presence of immunoglobulin M isotypes in 95% of CFS serum samples tested. The presence of immunoglobulin G and immunoglobulin A isotypes were also detected in a subset of the samples. Future studies will focus on elucidating whether alterations to mitochondrial inner membranes and/or metabolic functions play a possible role in the expression of ACAs. J. Clin. Lab. Anal. 23:210β212, 2009. Β© 2009 WileyβLiss, Inc.
π SIMILAR VOLUMES
To elucidate the specificity of anticardiolipin antibodies (aCL) from patients with the antiphospholipid syndrome (APS) to various phospholipids (PLs), DNA, and &-glycoprotein I (&-GPI). Methods. Five monoclonal aCL were established from peripheral blood lymphocytes of 3 patients with the APS. The
Antiphospholipid antibodies are a type of autoanti-thematosus and other autoimmune disorders but are bodies that have been implicated in the occurrence of being increasingly detected in patients without apparthrombocytopenia and thrombotic events and have been ent underlying autoimmune disease. 3,4
Two hundred and seventy-five patients fulfilling the Centre for Disease Control (CDC) criteria for Chronic Fatigue Syndrome (CFS) completed measures assessing illness history, global ratings of well being, sleep, activity and psychopathology at baseline, 6 months, 18 months and 3 year follow-up. For